(PatrioticPost.com)- Researchers from the National Institute of Allergy and Infectious Disease (NIAID) conducted a study last year that explained why the mRNA vaccines provide only short-lived protection against COVID-19 compared to natural immunity.
The mRNA vaccines, the study found, target COVID’s spike protein while natural immunity recognizes the entire virus, including the nucleocapsid protein that surrounds the RNA core.
According to the preprint published in April, the NIAID’s study found that for “any given viral copy number,” the odds of developing anti-nucleocapsid antibodies were 13.67 times higher for the unvaccinated than the vaccinated. Placebo recipients with a mild COVID infection had a 71 percent chance of developing anti-nucleocapsid antibodies while vaccinated recipients had only a 15 percent chance.
According to Just the News, the report on the NIAID study doesn’t appear to have gotten much coverage in the American corporate media, nor has the NIAID promoted the study.
Golly, what a shock.
The media and Dr. Fauci’s NIAID don’t want people to know that natural immunity provides better protection than the mRNA vaccines they’ve been pushing on the public for more than a year. Why would that be?
Last week, Dr. Fauci told CNN that some vaccines give “a very high degree of protection,” but conceded that the “durability isn’t very long.” He said short-lived immunity is an inherent disadvantage with the mRNA technology, but he also defended mRNA vaccines, calling the technology “a really great platform.”
Back in January, Bill Gates criticized the short-lived immunity provided by the COVID vaccines. In February, he pointed out that the Omicron variant has done more to provide immunity than the vaccines.
According to reporter Alex Berenson, the NIAID study may explain the reinfection rate among vaccinated Americans. The study, Berenson explained on Substack, shows that a vaccinated person would need almost “100,000 times as much virus” as a placebo recipient “to trigger the same chance of developing” the antibodies found in natural immunity.
Pfizer CEO Albert Bourla recently conceded that Pfizer’s mRNA vaccine wasn’t effective against the Omicron variant. Bourla also admitted that choosing mRNA technology for COVID was “counterintuitive.”